All Photos(1)

Documents

PHR1624

Cisplatin

Name: Cisplatin
Brand: SIAL

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Linear Formula:

Pt(NH₃)₂Cl₂

CAS Number:

15663-27-1

Molecular Weight:

300.05

EC Number:

239-733-8

MDL number:

MFCD00011623

UNSPSC Code:

41116107

PubChem Substance ID:

329823516

NACRES:

NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

300

Agency

traceable to Ph. Eur. C2210000
traceable to USP 1134357

API family

cisplatin

CofA

current certificate can be downloaded

packaging

pkg of 200 mg

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

270 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Certified Reference Materials

Pharmacopeia & Metrological Institute Standards

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.

Application

Cisplatin may be used as an analytical reference standard for the determination of the analyte in plasma, cancer cell, and tumor samples by high-performance liquid chromatographic assay.

These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAB7778 in the slot below. This is an example certificate only and may not be the lot that you receive.

related product

Product No.

Description

Pricing

Signal Word

Danger

Hazard Statements

H300,H315,H317,H319,H334,H335,H350

Precautionary Statements

P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.

Lopez-Flores A, et al.

Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)

Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma.

Sonja Ludwig et al.

Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)

Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)

Sample handling for determination of free platinum in blood after cisplatin exposure.

Johnsson A, et al.

Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)

The effects of proliferation status and cell cycle phase on the responses of single cells to chemotherapy.

Adrián E Granada et al.

Molecular biology of the cell, 31(8), 845-857 (2020-02-13)

DNA-damaging chemotherapeutics are widely used in cancer treatments, but for solid tumors they often leave a residual tumor-cell population. Here we investigated how cellular states might affect the response of individual cells in a clonal population to cisplatin, a DNA-damaging

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.

Jessica M Rusert et al.

Cancer research, 80(23), 5393-5407 (2020-10-14)

Medulloblastoma is among the most common malignant brain tumors in children. Recent studies have identified at least four subgroups of the disease that differ in terms of molecular characteristics and patient outcomes. Despite this heterogeneity, most patients with medulloblastoma receive

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service